Prussian blue (medical use)

This article is about the medical uses of the pigment. For the main article, see Prussian blue.
Prussian blue
Prussian blue
Clinical data
Trade namesRadiogardase, others
AHFS/Drugs.comMonograph
Routes of
administration		by mouth
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18Fe7N18
Molar mass859.24

Prussian blue, also known as potassium ferric hexacyanoferrate, is used as a medication to treat thallium poisoning or radioactive caesium poisoning.[1][2] For thallium it may be used in addition to gastric lavage, activated charcoal, forced diuresis, and hemodialysis.[3][4] It is given by mouth or nasogastric tube.[2][4] Prussian blue is also used in the urine to test for G6PD deficiency.[5]

Side effects may include constipation, low blood potassium, and stools that are dark.[1][3] With long-term use, sweat may turn blue.[3] It mainly works by trapping the toxic monovalent cations in its crystal lattice after ion-exchange with potassium or ammonium cations and thus preventing the absorption of thallium and radio-caesium from the intestines.[3]

Prussian blue was developed around 1706.[6] It is on the World Health Organization's List of Essential Medicines.[7] As of 2016, it is only approved for medical use in Germany, the United States, and Japan.[8][9][10] Access to medical-grade Prussian blue can be difficult in many areas of the world including the developed world.[11]

  1. ^ a b World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 65. hdl:10665/44053. ISBN 9789241547659.
  2. ^ a b Cite error: The named reference Ric2015 was invoked but never defined (see the help page).
  3. ^ a b c d "Prussian Blue". The American Society of Health-System Pharmacists. Archived from the original on 18 January 2017. Retrieved 8 January 2017.
  4. ^ a b Seifert SA (2004). "Elimination Enhancement". In Dart RC (ed.). Medical Toxicology. Lippincott Williams & Wilkins. p. 248,279. ISBN 9780781728454. Archived from the original on 2017-01-16.
  5. ^ "Glucose-6-phosphate dehyrogenase deficiency". Medlibes: Online Medical Library. 28 July 2010. Archived from the original on 2016-09-15. Retrieved 2017-05-03.
  6. ^ Hall AH, Isom GE, Rockwood GA (2015). "Physicochemical Properties, synthesis, applications, and transport". Toxicology of Cyanides and Cyanogens: Experimental, Applied and Clinical Aspects. John Wiley & Sons. p. 43. ISBN 9781118628942. Archived from the original on 2017-01-16.
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. ^ Angle CR (2016). "Organ-Specific Therapeutic Intervention". In Goyer RA (ed.). Metal Toxicology: Approaches and Methods. Elsevier. p. 93. ISBN 9781483288567.
  9. ^ Rusyniak DE (2009). "Thallium". In Dobbs MR (ed.). Clinical Neurotoxicology: Syndromes, Substances, Environments. Elsevier Health Sciences. p. 280. ISBN 978-0323052603.
  10. ^ Ruprecht J (1 July 2011). "Radioaktivität: Berliner Blau als Arzneimittel" [Radioactivity: Prussian Blue as a medicine]. Deutsches Ärzteblatt [German Medical Journal] (in German).
  11. ^ Kubiak WD (27 June 2011). "Fukushima's Caesium Spew - Deadly Catch-22s in Japan Disaster Relief". Truthout. Archived from the original on 23 August 2019.